Docking of hydroxamic acids into HDAC1 and HDAC8: A rationalization of activity trends and selectivities

Journal of Chemical Information and Modeling

Volumn 49, Issue 12, 2009, Pages 2774-2785

  Ortore, Gabriella ^a   Francesco Di, Colo ^a   Martinelli, Adriano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ENGINEERING; CHEMISTRY;

ANTICANCER DRUG; HDAC INHIBITORS; HISTONE DEACETYLASES; HOMOLOGY MODELING; HYDROXAMIC ACIDS; INHIBITORY ACTIVITY; LIGAND PROPERTIES; PROTEIN RESIDUES;

ISOENZYMES;

HDAC8 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LIGAND; REPRESSOR PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG ANTAGONISM; ENZYME SPECIFICITY; HUMAN; METABOLISM; MOLECULAR GENETICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRESSOR PROTEINS; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID; SUBSTRATE SPECIFICITY;

EID: 73349116582     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci900288e     Document Type: Article

References (60)

1. Kornberg, R. D.; Lorch, Y. Twenty-five years of the nucleosome, fundamental particle of the eukaryote chromosome. 1999, 98, 285-294.
2. Jenuwein, T.; Allis, C. D. Translating the histone code. Science 2001, 295, 1074-1080.
3. Peterson, C. L.; Laniel, M. A. Histones and histone modifications. Curr. Biol. 2004, 14, R546-551.
4. Strahl, K. Histone acetylation and transcriptional regulatory mechanism. Gene Dev. 1998, 12, 599-606. (Pubitemid 28134293)
5. Moggs, J. G.; Goodman, J. I.; Trosko, J. E.; Roberts, R. A. Epigenetics and cancer: implications for drag discovery and safety assessment. Toxicol. APPl, Pharmacol. 2004, 196, 422-1130
6. Brown, K. L.; Bren, U.; Stone, M. P.; Guengerich, F. P. Inherent stereospecificity in the reaction of anatoxin B1. 8,9-epoxide with deoxyguanosine and efficiency of DNA catalysis. Chem., Res. Toxicol. 2009, 22, 913-917.
7. Zhang, H.; Bren, U.; Kozekov, I. D.; Rizzo, C. J.; Stec, D. F.; Guengerich, F. P. Steile and electrostatic effects at the C2 atom substituent influence replication and miscoding of the DNA deamination product deoxyxanthosine and analogs by DNA polymerases. J. Mol. Biol. 2009, 392, 251-269.
8. North, B. J.; Marshall, B. L.; Borra, M. T.; Denu, J. M.; Verdin, E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol. Cell 2003, 11, 437-444 (Pubitemid 36293837)
9. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.-F.; Yao, T.-P. HDAC6 is a microtubuleassociated deacetylase. Nature 2002, 417, 455-458.
10. Holbert, M. A.; Marmorstein, R. Structure and activity of enzymes that remove histone modifications. Curr. Opin. Struct. Biol. 2005, 15, 673-680.
11. Marks, P. A.; Richon, V. M.; Miller, T.; Kelly, W. K. Histone deacetylase inhibitors. Adv Cancer Res. 2004, 91, 137-168.
12. Somech, R.; Izraeli, S.; Amos, J. S. Histone deacetylase inhibitors-a new tool to treat cancer. Cancer Treat. Rev. 2004, 30, 461-472. (Pubitemid 38968126)
13. Kelly, W. K.; Richon, V. M.; O'Connor, O.; Curley, T.; MacGregorCurtelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; Drobnjak, M.; Cordon-Cordo, C.; Chiao, J. H.; Rifkind, R.; Marks, P. A.; Scher, H. Phase I Clinical Trial of Histone Deacetylase Inhibitor: Suberoylanilide Hydroxamic Acid Administered Intravenously. Clin. Cancer- 2003, 9, 3578-3588. (Pubitemid 37169221)
14. Gore, S. D.; Weng, L.-.I.; Zhai, S.; Figg, W. D.; Donehower, R. C.; Dover, G. J.; Grever, M.; Griffin, C. A.; Grochow, L. B.; Rowinsky, E. K.; Zabalena, Y.; Hawkins, A. L.; Burks, K.; Miller, C. B. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 2001, 7, 2330-2339.
15. Pauer, L. R.; Olivares, J.; Cunningham, C.; Williams, A.; Grove, W.; Kraker, A.; Olson, S.; Nemunaitis, J. Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with, advanced solid tumors. Cancer Invest.- 2004, 22, 886-896. (Pubitemid 39665354)
16. Richards, D. A.; Boehm, K. A.; Waterhouse, D. M.; Wagener, D. J.; Krishnamurthi, S. S.; Rosemurgy, A.; Grove, W.; Macdonald, K.; Gulyas, S.; Clark, M.; Dasse, K. D. Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, doubleblind, placebo-controlled, multicenter study. Ann. Oncol. 2006, 17, 1096-1102.
17. Marshall, J. L.; Rizvi, N.; Kauh, J.; Dahut, W.; Figuera, M.; Rang, M. H.; Figg, W. D.; Wainer, I.; Chaissang, C.; Li, M. Z.; Hawkins, M. J. A phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Em. Ther. Oncol. 2002, 2, 325-332. (Pubitemid 35265981)
18. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401, 188-193.
19. Nielsen, T. K.; Hildmann, C.; Dickmanns, A.; Schwienhorst, A.; Ficner, R. J. Crystal structure of a bacterial class 2 histone deacetylase homologue. J. Mol. Biol. 2005, 354, 107-120.
20. Somoza, J. R.; Skene, R. J.; Katz, B. A.; Mol, C.; Ho, J. D.; Jennings, A. J.; Luong, C.; Arvai, A.; Buggy, E.; Chi, J.; Tang, B. C.; Sang, E.; Verner, R.; Wynands, E. M.; Leahy, D. R.; Dougan, G.; Snell, M.; Navre, J. J.; Knuth, M. W.; Swanson, R. V.; McRee, D. E.; Tari, L. W. Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases. Structure 2004, 12, 1325-1334.
21. Bottomley, M. J.; Lo Surdo, P.; Di Giovine, P.; Grillo, A.; Scarpelli, R.; Ferrigno, F.; Jones, P.; Neddermann, P.; De Francesco, R.; Steinkuhler, C.; Gallinari, P.; Carfi, A. Structural and Functional Analysis of the Human Hdac4 Catalytic Domain. Reveals a Regulatory Zinc-Binding Domain. J. Biol. Chem. 2008, 283, 26694-26704.
22. Schuetz, A.; Min, J. R.; Allali-Hassani, A.; Loppnau P.; Kwiatkowski, N. P.; Mazitschek, R.; Edwards, A. M.; Arrowsmith, C. H.; Vedadi, M.; Bochkarev, A. Plotnikov, A. N. Crystal structure of the human histone deacetylase IIDAC7. Manuscript in preparation.
23. Wang, D. F.; Helquist, P.; Wiech, N. L.; Wiest, O. Toward selective histone deacetylase inhibitor design: homology modeling, docking studies, and molecular dynamics simulations of human class I histone deacetylases. J. Med. Chem. 2005, 48, 6936-6947. (Pubitemid 41533115)
24. Wu, T. Y. H.; Hassig, C.; Wu, Y.; Ding, S.; Schultz, P. G. Design, synthesis, and activity of HDAC inhibitors with, a N-formyl hydroxylamine head group. Bioorg. Med, Chem., Lett. 2004, 14, 449-453.
25. Kozikowski, A. P.; Chen, Y.; Gaysin, A. M.; Savoy, D. N.; Billadeau, D. D.; Kim, K. H. Chemistry, biology, and QSAR studies of substituted biaryl hydroxamates and mercaptoacetamides as HDAC inhibitorsnanomolar-potency inhibitors of pancreatic cancer cell growth. ChemMedChem 2008, 3, 487-501.
26. Chen, D.; Deng, W.; Sangthongpitag, K.; Song, H. Y.; Sun, E. T.; Yu, N.; Zou, Y. Benzimidazole derivatives: preparation and pharmaceutical application. WO Patent 2005/028447, Mar 31, 2005.
27. Deng, W.; Chen, D.; Zhou, Y. Bicyclic heterocycles: preparation, and pharmaceutical application. WO Patent 2006/101456, Sep 28, 2006.
28. Buggy, J. J.; Balasubramanian, S.; Verner, E.; Tai, V. W.-F.; Lee, C.-S. Indole derivatives as inhibitors of histone deacetylase. WO Patent 2007/109178, Sep 27, 2007.
29. KrennIIrabec, K.; Marshall, B. L.; Hedglin, M.; Verdin, E.; Ulrich, S. M. Design and Evaluation of 'Linkerless' hydroxamic acids as selective HDAC8 inhibitors. Bioorg., Med. Chem. Lett. 2007, 17, 2874-2878.
30. Sternson, S. M.; Wong, J. C.; Grozinger, C. M.; Schreiber, S. L. Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Ore. Lett. 2001, 3, 4239-4242.
31. Haggarty, S. J.; Koeller, K. M.; Wong, J. C.; Grozinger, C. M. Schreiber, S. L. Domain-selective small-molecule inhibitor of histone deactylase 6 (HDAC6)-mediated tubulin deacetylation. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 4389-4394.
32. Hu, E.; Dul, E.; Sung, C.-M.; Chen, Z.; Kirkpatrick, R.; Zhang, G.F.; Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; De Los Frailes, M.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of Novel Isoform-Selective Inhibitors within Class I Histone Deacetylases. J. Pharmacol. Exp. Ther- 2003, 307, 720-728. (Pubitemid 37310689)
33. Waltregny, D.; De Leval, L.; Glenisson, W.; Ly Tran, S.; North, B. J.; Bellahcene, A.; Weidle, U.; Verdin, E.; Castronovo, V. Expression of Histone Deacetylase 8, a Class I Histone Deacetylase, Is Restricted to Cells Showing Smooth Muscle Differentiation in Normal Human Tissues. Am. J. Pathol- 2004, 165, 553-564. (Pubitemid 38971385)
34. Waltregny, D.; Glenisson, W.; Tran, S. L.; North, B. J.; Verdin, E.; Colige, A.; Castronovo, V. Histone deacetylase HDAC8 associates with smooth muscle-actin and is essential for smooth muscle cell contractility. FASEB J. 2005, 19, 966-968. (Pubitemid 40827719)
35. Durst, K. L.; Lutterbach, B.; Kummalue, T.; Friedman, A. D.; Hiebert, S. W. The inv(16) Fusion Protein Associates with Corepressors via a Smooth Muscle Myosin Heavy-Chain Domain. Mol. Cell. Biol. 2003, 23, 607-619.
36. Kishimoto, M.; Kohno, T.; Okudela, K.; Otsuka, A.; Saski, H.; Tanabe, C.; Sakiyama, T.; Hirama, C.; Kitabayashi, I.; Minna, J. D.; Takenoshita, S.; Yokota, J. Mutations and deletions of the CBP gene in human lung cancer. Clin. Cancer Res. 2005, 11, 512-519. (Pubitemid 40116874)
37. Ishihama, K.; Yamakawa, M.; Semba, S.; Takeda, H.; Kawata, S.; Kimura, S.; Kimura, W. Expression of HDACl and CBP/p300 in human colorectal carcinomas. J. Clin. Pathol. 2007, 60, 1205-1210. (Pubitemid 350084539)
38. Zhu, P.; Martin, E.; Mengwasser, J.; Schlag, P.; Janssen, K.-P.; Göttlicher, M. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 2004, 5, 455-463. (Pubitemid 38610247)
39. Senese, S.; Zaragoza, K.; Minardi, S.; Muradore, I.; Ronzoni, S.; Passafaro, A.; Bernard, L.; Draetta, G. F.; Alcalay, M.; Seiser, C.; Chiocca, S. Role for Histone Deacetylase 1 in Human Tumor Cell Proliferation. Mol. Cell. Biol. 2007, 27, 4784-4795. (Pubitemid 47016131)
40. Ropero, S.; Fraga, M. F.; Ballestar, E.; Hamelin, R.; Yamamoto, H.; Boix-Chornet, M.; Caballero, R.; Alaminos, M.; Setien, F.; Paz, M. F.; Herranz, M.; Palacios, J.; Arango, D.; Orntoft, T. F.; Aaltonen, L. A.; Schwartz, Jr. S.; Esteller, M. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet. 2006, 38, 566-569.
41. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E. C.; Branetti, M.; Renzoni, R.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkuhler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with ahydroxamic acid inhibitor. Proc Natl. Acad. Sci. U.S.A. - 2004, 101, 15064-15069. (Pubitemid 39391719)
42. Vannini, A.; Volpari, C.; Gallinari, P.; Jones, P.; Mattu, M.; Carfi, A.; Defrancesco, R.; Steinkuhler, C.; Di Marco, S. Substrate binding to histone deacetylases as shown by the crystal structure of the HDAC8-substrate complex. EMBO Rep. 2007, 8, 879-884. (Pubitemid 350001433)
43. Dowling, D. P.; Gantt, S. L.; Gattis, S. G.; Fierke, C. A.; Christiansen, D. W. Structural studies of human histone deacetylase 8 and its sitespecific variants complexed with substrate and inhibitors. Biochemistry 2008, 47, 13554-13563.
44. Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T. N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. The Protein Data Bank. Nucleic Acids Res.- 2000, 28, 235-242.
45. Maestro, ver. 7.5; Schrödinger Inc.: Portland, OR, 1999.
46. Macromodel, ver. 8.5; Schrödinger Inc.: Portland, OR, 1999.
47. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson, A. J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput Chem. 1998, 19, 1639-1662.
48. Jones, G.; Willett, P.; Glen, R. C.; Leach, A. R.; Taylor, R. J. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
49. Huang, C. C.; Couch, G. S.; Pettersen, E. F.; Ferrin, T. E. The object technology framework: an object-oriented, interface to molecular data and its application to collagen. Pac. Symp. Biocomput. 1996, 1, 724; http://www.cgl.ucsf.edu/chimera
50. Soeding, J. Protein homology detection by HMM-HMM comparison. Bioinformatics 2005, 21, 951-960.
51. Hughey, R.; Krogh, A. Hidden. Markov models for sequence analysis: Extension and analysis of the basic method. Computer Arml. Biosci. 1996, 12, 95-107. (Pubitemid 26166723)
52. Altschul, S. F.; Madden, T. L.; Schärfer, A. A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acid Res. 1997, 25, 3389-3402. (Pubitemid 27359211)
53. Fiser, A.; Do, R. K.; Sali, A. Modeling of loops in protein, structures. Protein Sci. 2000, 9, 1753.
54. GOLPE, Version 4.5; Multivariate Infometric Analysis Srl.: Perugia, Italy, 1999.
55. GRID, Version. 22a; Molecular Discovery Ltd.: West Way House, Elms Parade, Oxford, U.K., 2004.
56. Estiu, G.; Greenberg, E.; Harrison, C. B.; Kwiatkowski, N. P.; Mazitschek, R.; Bradner, J. E.; Wiest, O. Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J. Med. Chem. 2008, 51, 2898-2906. (Pubitemid 351706018)
57. Tuccinardi, T.; Nuti, E.; Ortore, G.; Rossello, A.; Avramova, S. I.; Martinelli, A. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors. Bioorg. Med. Chem. Lett. 2008, 16, 7749-7758.
58. Ragno, R.; Mai, A.; Massa, S.; Cerbara, I.; Valente, S.; Bottoni, P.; Scatena, R.; Jesacher, F.; Loidl, P.; Brosch, G. 3-(4-Aroyl-l-methyl1H-pyrrol-2- yl)-N-hydroxy-2-propenamides as a New Class of Synthetic Histone Deacetylase Inhibitors. 3. Discovery of Novel Lead Compounds through Structure-Based Drag Design and Docking Studies. J. Med. Chem 2004, 47, 1351-1359. (Pubitemid 38327463)
59. Heltweg, B.; Dequiedt, F.; Marshall, B. L.; Brauch, C.; Yoshida, M.; Nishino, N.; Verdin, E.; Jung, M. Subtype selective substrates for histone deacetylases. J. Med Chem 2004, 47, 5235-5243. (Pubitemid 39314921)
60. Blackwell, L.; Noms, J.; Suto, M. C.; Janzen, W. P. The use of diversity profiling to characterize chemical modulators of the histone deacetylases. Life Sci. 2008, 82, 1050-1058.